NIDAN

Nidan Laboratories and Healthcare Limited

Listed company · ISIN INE0J6L01013 · NSE SM · FV ₹10
Last price
₹13
-0.78%today
What this company does

Nidan Laboratories and Healthcare Limited is a listed company. It booked ₹26 cr of revenue in its latest year (FY26) and kept 5.9% of sales as profit.

56out of 100
Equitytale Health Score
Mixed

Healthier than 56% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,387–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
48

At close. Not part of the score.

Profitability & returns32

How much profit it earns on the money it employs

Balance sheet45

How much it owes, and whether earnings cover the interest

Cash quality58

Whether reported profit actually arrives as cash

Valuation81

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
A mixed picture
Strengths
✓ Makes a profit
✓ Promoters hold 57%
✓ No promoter shares pledged
✓ Turns profit into real cash
Watch-outs
! Thin 5.9% net margin
! Low 2.7% return on equity

What if I invest in NIDAN?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 5% a year, it would become
₹15.50 lakh

The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest full year + price
₹13▼ -0.78%
latest close · 2026-11-04
52-wk low ₹12222 sessions so far52-wk high ₹124
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio11.9Low
LowAverageHigh
P/B ratio0.32Below book
Below bookModerateHigh
EV / EBITDA6.1Low
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity2.7%Weak
WeakFairStrong ▸15%
Return on capital6.0%Weak
WeakFairStrong
Net margin5.9%Decent
ThinDecentStrong
EBITDA margin17.2%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.20Comfortable
LowModerateHigh ▸1
Interest cover2.2×Okay
RiskyOkayStrong ▸5×
Current ratio1.43Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹18 cr
Book value
₹40
EPS
₹1.08
latest full year
Net debt
₹9 cr
owes more than its cash
Enterprise value
₹27 cr
EBITDA
₹4 cr
latest full year
EBIT
₹4 cr
latest full year
Operating margin
17.2%
Return on assets
1.8%
Earnings yield
8.44%
P/S
0.70
Sales / share
₹18.4
Tax rate
38.4%
Face value
₹10
Shares
1.4 cr
Working capital
₹4 cr
Current assets
₹15 cr
Current liabilities
₹10 cr
Delivery %
81.2%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are from the latest full-year results; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹8–₹8, midpoint ₹8

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · FY26 (consolidated)
Revenue from Operations₹26 cr
Other Income₹2 cr
Total Income₹27 cr
Cost of Materials₹98.3 L
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹1.7 L
Employee Benefit Expense₹4 cr
Finance Costs₹2 cr
Other Expenses₹15 cr
Total Expenses₹25 cr
Profit before Tax₹2 cr
Tax Expense₹93.8 L
Net Profit₹2 cr
Net margin on total income5.5%
Where the money goes · FY26
% of total income
Materials + stock-in-trade₹100 L3.7%
Employee benefit expense₹4 cr15.9%
Finance costs₹2 cr7.2%
Other expenses₹17 cr64.1%
Tax expense₹93.8 L3.5%
Profit for the period₹2 cr5.6%
Total income ₹27 cradds up to ₹100 ✓
Annual results · consolidated (₹ cr)
MetricFY25FY26
Revenue25 cr26 cr
Total income27 cr27 cr
Expenses24 cr25 cr
Profit before tax3 cr2 cr
Tax78.3 L93.8 L
Net profit (owners' share)2 cr2 cr
Net margin (owners' share, on revenue)8.1%5.9%
EPS (₹)1.421.08
YoY (latest year): total income +2.3% · net profit -23.8%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹84 cr
Shareholder equity
₹56 cr
parent shareholders
Total debt
₹11 cr
Cash
₹2 cr
Cash flow · H1 FY25
Operating
₹1 cr
Investing
₹0.35 L
Financing
₹-2 cr
Who owns it · 2026-09-30
No pledge
Promoter
57.0%
FII / Foreign
0.0%
DII / Domestic
0.0%
Retail / others
43.0%
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 28 Sep 2026
See the official result
1
TO RECEIVE CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2026 AND THE REPORTS OF THE AUDITORS AND DIRECTORS THEREON
Backed by 99% of shareholders other than promotersneeded 50%
1.74 L votes for, 2,000 against
2
TO APPOINT A DIRECTOR IN PLACE OF MS. TEJAL JAYAKAR (DIN 07984686) WHO RETIRES BY ROTATION AND BEING ELIGIBLE OFFERS HERSELF FOR RE-APPOINTMENT
Backed by 99% of shareholders other than promotersneeded 50%
1.74 L votes for, 2,000 against
3
RE-APPOINTMENT OF M/S R. K. CHAPAWAT AND CO. CHARTERED ACCOUNTANTS (FIRM REGISTRATION NUMBER 101708W) AS THE STATUTORY AUDITORS OF THE COMPANY
Backed by 99% of shareholders other than promotersneeded 50%
1.74 L votes for, 2,000 against
4
TO APPROVE THE RE-APPOINTMENT OF MR. NILESH BIDE (DIN 06366702) AS A NON EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY FOR THE 2ND TERM OF 5 (FIVE) YEARS W.E.F. 20TH AUGUST 2026
Backed by 99% of shareholders other than promotersneeded 75%
1.74 L votes for, 2,000 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 9 named members
owning 57.0% between them · as of 2026-09-30
NITIN VITTHALRAO THORVE50.15%
ROSHAN NITIN THORVE6.89%
ABHILASHA NITIN THORAVEno shares
EDWIN FRANCIS DABREno shares
HARIPRIT NITIN THORAVEno shares
KRUPESH DEEPAK THAKURno shares
LATA VITTHAL HANDEno shares
TEJAL ANIL JAYAKARno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.